Filament Health

Psychedelics have long been relatively ostracized from modern medicine, however, this wasn’t always the case. In the early 1900s, psychedelic research was thriving, unfortunately, during the past 50 years, we’ve seen a total blackout in the industry. Now, this standstill is coming to an end as we step into a new psychedelic renaissance with dozens of companies leading the thriving space. For investors, this is a key moment to scoop up some of the most innovative companies before they take off.

Enter Filament Health (NEO: FH), a leader in the field of psychedelics and a company uniquely poised for growth thanks to their one-of-a-kind all-natural approach. Filament is working to further all-natural psychedelics which have been proven to afford greater efficacy over its many synthetic competitors. Although there is a larger number of combinations for synthetic compounds, artificial psychedelics have a failure rate of up to 90%. This is greater than that of their natural counterparts. Furthermore, plant-based treatments already have a strong history of success such as Taxol, the best-selling cancer treatment ever, which is extracted from the Yew tree. This, alongside the 40% of all Western pharmaceuticals that are derived from plants, speaks to the storied success of all-natural health treatments.

Filament’s work with all-natural psychedelic health treatments comes at a particularly opportune moment. Mental health has been an increasingly important issue, more so than ever during the COVID pandemic. Globally there are 560 million people suffering from either depression, anxiety, or addiction, and an excess of $8.5 billion is spent annually in treatment. Filament’s all-natural psychedelics, however, may be able to address this problem more effectively. Over 130 active clinical trials are demonstrating or looking to demonstrate the greater efficacy and health benefits of psychedelics compared to current treatments. Indeed, such results are positive for the outlook of Filament Health’s work and the greater field of psychedelics in healthcare treatment. With this positive tailwind, Filament’s foundation in the field serves as a great platform to pioneer the natural psychedelics sector. Filament possesses a world-leading natural psychedelics IP portfolio, novel purification methods, and a robust botanical extraction management team. With this framework, Filament is poised to lead the research into the rapidly expanding world of natural psychedelic plants.

With nature taking the wheel, going back to natural remedies may be for the best. Nature has been providing safe and effective remedies for healthcare issues for millennia and now companies such as Filament Health are working to make this resource accessible. With a growing mental health crisis and the need for more effective treatment methods, Filament’s all-natural approach makes it a solid investment for those looking to snag a piece of this key sector of healthcare.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for Our Newsletters

Get exclusive content in your inbox.

You May Also Like

DiDi Stock Price Forecast: Buy the Dip or Sell the Rip?

The DiDi stock price has dropped sharply after the latest crackdown by China. We explain the motive behind the crackdown and what to expect.

5 Stocks to Watch This Week: SFIX, GME, AMC, Chewy, AAP

Stitch Fix, GameStop, Chewy, and Advance Auto parts will publish their first-quarter earnings while Monday.com and TaskUs will launch their IPOs.

Alibaba Stock Price Analysis: A Better Buy than Amazon

Alibaba stock price is in a bear territory as the Chinese government crackdown intensifies. We explain why it is a better buy than Amazon.

Plug Power Stock Price Forecast After Mixed Earnings

Plug Power stock price rose by more than 7% after it released mixed quarterly results. We explain what to expect now that it is stuck at the 200 EMA.